Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles

References

• World Health Organization. The World Health Report 2004: Changing History. World Health Organization, Geneva, Switzerland (2004).
   Google Scholar
• Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD. Deaths: Final Data for 2001. CDC National Vital Statistics Reports 52(3), 30–33 (2003).
   Google Scholar
• Anderson RN, Smith BL. Deaths: Leading Causes for 2001. CDC National Vital Statistics Reports 52(9), (2003).
   Google Scholar
• Kochanek KD, Smith BL. Deaths: Final Data for 2002. CDC National Vital Statistics Reports 53(5),, 29–32 (2004).
   Google Scholar
• Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. 43(Suppl. A), 97–105 (1999).
   PubMed Web of Science ®Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117, 380S–385S (2000).
   Google Scholar
• Anon JB, Jacobs MR, Poole MD et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. 130, 1–45 (2004).
   PubMed Web of Science ®Google Scholar
• McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. J. Am. Med. Assoc. 273, 214–219 (1995).
   PubMed Web of Science ®Google Scholar
• Scott Levin Prescription Audit from Verispan, LLC. January–December 2002.
   Google Scholar
• Howie VM, Ploussard JH. The ‘in vivo sensitivity test’–bacteriology of middle ear exudate, during antimicrobial therapy in otitis media. Pediatrics 44, 940–944 (1969).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect. Dis. 2, 593–604 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. Clin. Lab. Med. 24, 419–453 (2004).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis. 31, 347–382 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. Emergence of antibiotic resistance in upper and lower respiratory tract infections. Am. J. Manage. Care 5, S651–S661 (1999).
   PubMed Web of Science ®Google Scholar
• Naraqi S, Kirkpatrick GP, Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. J. Pediatr. 85, 671–673 (1974).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52, 229–246 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Zilles A et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance study. Antimicrob. Agents Chemother. 43, 1901–1908 (1999).
   PubMed Web of Science ®Google Scholar
• Jones ME, Karlowsky JA, Blosser-Middleton R et al. Apparent plateau in β-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int. J. Antimicrob. Agents 19, 119–123 (2002).
   PubMed Web of Science ®Google Scholar
• White AR, Kaye C, Poupard J et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl. 1), I3–I20 (2004).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37, 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163, 1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125, 1888–1901 (2004).
   PubMed Web of Science ®Google Scholar
• Flanders SA, Halm EA. Guidelines for community-acquired pneumonia: are they reflected in practice? Treat. Respir. Med. 3, 67–77 (2004).
   PubMedGoogle Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160, 1399–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Donowitz GR, Brandon ML, Salisbury JP et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin. Ther. 19, 936–953 (1997).
   PubMed Web of Science ®Google Scholar
• Lode H, Garau J, Grassi C et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin–clavulanic acid and erythromycin. Eur. Respir. J. 8, 1999–2007 (1995).
   PubMed Web of Science ®Google Scholar
• Mundy LM, Oldach D, Auwaerter PG et al. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest 113, 1201–1206 (1998).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect. Dis. Clin. North Am. 12, 569–592 (1998).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Pratt HM, Obrosky DS et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am. J. Med. 109, 378–385 (2000).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20, 820–837 (1998).
   PubMed Web of Science ®Google Scholar
• Easton J, Noble S, Perry CM. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs 63, 311–340 (2003).
   PubMed Web of Science ®Google Scholar
• Kaye CM, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23, 578–584 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. How can we predict bacterial eradication? Int. J. Infect. Dis. 7(Suppl. 1), S13–S20 (2003).
   PubMedGoogle Scholar
• Augmentin XR™, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2002).
   Google Scholar
• File T, Lode H, Kurz H, Crann R and Group ATS. Comparative efficacy/safety of pharmacokinetically enhanced amoxicillin/clavulanate 200/125 mg vs. amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP). Presented at the 99th International Conference of the American Thoracic Society. 16 (2003)
   Google Scholar
• Petitpretz P, Chidiac C, Soriano F et al. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int. J. Antimicrob. Agents 20, 119–129 (2002).
   PubMed Web of Science ®Google Scholar
• Garau J, Twynholm M, Garcia-Mendez E and ATS Group. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg b.d. versus amoxicillin/clavulanate 875/125 mg t.d.s. in community-acquired pneumonia (CAP). Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy, April 24–27 (2002).
   Google Scholar
• File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. Int. J. Antimicrob. Agents 20, 235–247 (2002).
   PubMed Web of Science ®Google Scholar
• Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab. Med. 24, 477–502 (2004).
   PubMed Web of Science ®Google Scholar
• Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365, 855–863 (2005).
   Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar